<DOC>
	<DOCNO>NCT01042730</DOCNO>
	<brief_summary>The purpose study evaluate prevention cardiovascular disease moderate cholesterol lower therapy , pitavastatin 1mg/day aggressive cholesterol lower therapy , pitavastatin 4mg/day patient stable coronary artery disease .</brief_summary>
	<brief_title>Randomized Evaluation Aggressive Moderate Lipid Lowering Therapy With Pitavastatin Coronary Artery Disease ( REAL-CAD )</brief_title>
	<detailed_description>It already demonstrate previous clinical trial statin low incidence death cardiovascular event patient coronary artery disease . However , whether aggressive cholesterol lower therapy , use high dosage statin , effective moderate cholesterol lower therapy prevention cardiovascular event patient coronary artery disease study Japan .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Patients meet follow criterion enter runin period , load pitavastatin 1 mg/day 1 month inform consent give . ( Primary registration ) Coronary artery disease patient meet one follow event History Acute Coronary Syndrome ( AMI Unstable angina ) History revascularization ( PCI CABG ) Diagnosis ischemic heart disease coronary artery stenosis 75 % high stenosis accord AHA classification Hypercholesterolemia patient meet one follow criterion LDLC 140 mg/dL LDLC 100 mg/dL require cholesterol lower drug judge attend physician Patents receive cholesterol lower drug Age ( ≧20 ＜80 yearold ) Patients give write informed consent . Exclusion Criteria ( PreRunin period ) Patients plan revascularization Malignant tumor active phase Patients meet contraindication LIVALO tablet Patients hypersensitivity LIVALO tablet Patients severe liver dysfunction biliary atresia Patients treat cyclosporine Pregnant woman , woman suspect pregnant , lactating woman Patients heart failure NYHA III great Patients undergoing dialysis Patients familial hypercholesterolemia Patients register clinical trial Patients take prohibited drug Patients ineligible opinion investigator Exclusion Criteria ( PostRunin period ) LDLC 120mg/dL Runin period Patients occurrence acute coronary syndrome ( AMI Unstable angina ) within 3 month Patients undergone PCI CABG within 3 month Compliance less 50 % Runin period Patients meet primary endpoint Runin period . Patients meet adverse event Runin period judge ineligible opinion investigator Patients ineligible opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Pitavastatin</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Cardiovascular Disease</keyword>
</DOC>